Manages pain severe enough to require an opioid analgesic. ANDA 210176, held by Ascent Pharmaceuticals. Hydromorphone Hydrochloride.
As of Nov 18, 2026, ANDA 210176 (Hydromorphone Hydrochloride), held by Ascent Pharmaceuticals, was first approved by FDA on Oct 27, 2017, with 4 approved supplements and 0 published complete response letters.
Hydromorphone Hydrochloride Oral Solution are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Hydromorphone Hydrochloride Oral Solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydromorphone Hydrochloride5MG/5ML · solution;oral | Hydromorphone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 7REMS | Approved | None posted |
| Mar 13, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 3REMS | Approved | None posted |
| Sep 18, 2018 | Supplement 2REMS | Approved | None posted |
| Oct 27, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters